Büchold, C.; Hils, M.; Gerlach, U.; Weber, J.; Pelzer, C.; Heil, A.; Aeschlimann, D.; Pasternack, R.
Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells 2022, 11, 1667.
https://doi.org/10.3390/cells11101667
AMA Style
Büchold C, Hils M, Gerlach U, Weber J, Pelzer C, Heil A, Aeschlimann D, Pasternack R.
Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells. 2022; 11(10):1667.
https://doi.org/10.3390/cells11101667
Chicago/Turabian Style
Büchold, Christian, Martin Hils, Uwe Gerlach, Johannes Weber, Christiane Pelzer, Andreas Heil, Daniel Aeschlimann, and Ralf Pasternack.
2022. "Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease" Cells 11, no. 10: 1667.
https://doi.org/10.3390/cells11101667
APA Style
Büchold, C., Hils, M., Gerlach, U., Weber, J., Pelzer, C., Heil, A., Aeschlimann, D., & Pasternack, R.
(2022). Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease. Cells, 11(10), 1667.
https://doi.org/10.3390/cells11101667